Skip to content

Brain function fingerprinting and its clinical significance in patients with mild cognitive impairment based on resting state fMRI

Brain function fingerprinting and its clinical significance in patients with mild cognitive impairment based on resting state fMRI

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900027264
Enrollment
Unknown
Registered
2019-11-07
Start date
2020-01-01
Completion date
Unknown
Last updated
2019-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mild cognitive impairment

Interventions

Sponsors

The Affiliated Suzhou Science & Technology Town Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: According to the 2003 International Working Group MCI diagnostic criteria, it mainly includes the following four points: 1. Insider of the patient, or an experienced clinician reports cognitive impairment; 2. There is objective evidence of damage to one or more cognitive domains (from cognitive tests); 3. Complex instrumental daily abilities can be slightly damaged, but maintain independent daily living ability; 4. The diagnosis of dementia has not yet been reached.

Exclusion criteria

Exclusion criteria: 1. Hypertensive patients with uncontrollable blood pressure (systolic blood pressure greater than 160mmHg or diastolic blood pressure greater than 100mmHg); 2. Have a history of alcohol and drug abuse; 3. Have a history of mental illness (such as personality disorder, schizophrenia, etc.), or have severe aphasia and audio-visual disorders, or severe organ failure, history of myocardial infarction, history of coronary heart disease, musculoskeletal disorders and other contraindications; 4. Cognitive impairment caused by depression, that is, the old age depression scale (ODS) >= l1; 5. People with cognitive impairment caused by drugs or poisoning; 6. are participating in other clinical trials that influence the evaluation of the results of this study.

Design outcomes

Primary

MeasureTime frame
Brain function fingerprinting;MoCA;

Countries

China

Contacts

Public ContactZenglin Cai

The Affiliated Suzhou Science & Technology Town Hospital of Nanjing Medical University

caizengling@163.com+86 19951296073

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026